ATE208824T1 - Für proteine des menschlichen papillomavirus kodierende rekombinante virusvektoren - Google Patents

Für proteine des menschlichen papillomavirus kodierende rekombinante virusvektoren

Info

Publication number
ATE208824T1
ATE208824T1 AT92906294T AT92906294T ATE208824T1 AT E208824 T1 ATE208824 T1 AT E208824T1 AT 92906294 T AT92906294 T AT 92906294T AT 92906294 T AT92906294 T AT 92906294T AT E208824 T1 ATE208824 T1 AT E208824T1
Authority
AT
Austria
Prior art keywords
virus vector
pct
nucleotide sequences
recombinant virus
pair
Prior art date
Application number
AT92906294T
Other languages
English (en)
Inventor
Michael Edward Griff Boursnell
Stephen Charles Inglis
Alan James Munro
Original Assignee
Cantab Pharmaceuticals Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Pharmaceuticals Res Ltd filed Critical Cantab Pharmaceuticals Res Ltd
Application granted granted Critical
Publication of ATE208824T1 publication Critical patent/ATE208824T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/004—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT92906294T 1991-03-14 1992-03-10 Für proteine des menschlichen papillomavirus kodierende rekombinante virusvektoren ATE208824T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919105383A GB9105383D0 (en) 1991-03-14 1991-03-14 An immunotherapeutic for cervical cancer
PCT/GB1992/000424 WO1992016636A1 (en) 1991-03-14 1992-03-10 Recombinant virus vectors encoding human papillomavirus proteins

Publications (1)

Publication Number Publication Date
ATE208824T1 true ATE208824T1 (de) 2001-11-15

Family

ID=10691550

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92906294T ATE208824T1 (de) 1991-03-14 1992-03-10 Für proteine des menschlichen papillomavirus kodierende rekombinante virusvektoren

Country Status (17)

Country Link
US (1) US5719054A (de)
EP (1) EP0576471B1 (de)
JP (1) JPH06505626A (de)
KR (1) KR100240183B1 (de)
CN (1) CN1090239C (de)
AT (1) ATE208824T1 (de)
AU (1) AU665531B2 (de)
BR (1) BR9205771A (de)
CA (1) CA2106069A1 (de)
DE (1) DE69232201T2 (de)
DK (1) DK0576471T3 (de)
ES (1) ES2168258T3 (de)
GB (1) GB9105383D0 (de)
MX (1) MX9205131A (de)
NO (1) NO310033B1 (de)
OA (1) OA10085A (de)
WO (1) WO1992016636A1 (de)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023570A1 (en) * 1992-05-11 1993-11-25 Pharmagenics, Inc. Oligonucleotides having conjugates attached at the 2'-position of the sugar moiety
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
AT399656B (de) * 1993-03-19 1995-06-26 Boehringer Ingelheim Int Verfahren zur herstellung von krebsvakzinen
US8956621B2 (en) * 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
JP3958360B2 (ja) * 1995-02-24 2007-08-15 キャンタブ ファーマシューティカルズ リサーチ リミティド 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
CZ28899A3 (cs) * 1996-07-29 1999-07-14 Cantab Pharmaceuticals Research Limited Polypeptidy použitelné jako imunoterapeutická činidla a způsoby přípravy polypeptidů
US7118754B1 (en) * 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
DE19631357A1 (de) * 1996-08-02 1998-02-05 Deutsches Krebsforsch Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen
MY150893A (en) * 1996-09-24 2014-03-14 Bavarian Nordic As Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
DE69829995T2 (de) * 1997-12-01 2006-02-23 Fang, Fang, San Diego Multivalente rekombinante antikörper zur behandlung von hrv infektionen
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CN101818145A (zh) * 1998-03-20 2010-09-01 联邦科学和工业研究组织 控制基因表达
WO1999049891A1 (en) * 1998-03-30 1999-10-07 Thomas Jefferson University Compositions and methods for providing a vpr-binding protein to a virion
DE19819476C1 (de) * 1998-04-30 2000-01-05 Deutsches Krebsforsch Polypeptid mit immunogenen Eigenschaften und veränderten biologischen Funktionen eines Proteins
SI1108035T1 (sl) * 1998-09-04 2007-12-31 Sanofi Pasteur Ltd Zdravljenje raka materničnega vratu
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
CA2384987A1 (en) * 1999-09-16 2001-03-22 Zycos Inc. Nucleic acids encoding polyepitope polypeptides
AU2007201619B2 (en) * 1999-09-16 2011-05-12 Eisai Inc. Nucleic acids encoding polyepitope polypeptides
WO2001068828A2 (en) 2000-03-13 2001-09-20 Engene, Inc. Compositions and methods for regulated protein expression in gut
AU2001249389A1 (en) * 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
GB0105606D0 (en) * 2001-03-07 2001-04-25 Cantab Pharmaceuticals Res Ltd Immunogens and vaccines and their preparation and use
AU2002252370A1 (en) * 2001-03-12 2002-09-24 Irm, Llc. Genomics-driven high speed cellular assays, development thereof, and collections of cellular reporters
AU2002254212A1 (en) * 2001-03-12 2002-09-24 Irm, Llc Identification of cellular targets for biologically active molecules
WO2002077012A2 (en) * 2001-03-23 2002-10-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Human papilloma virus immunoreative peptides
US8771702B2 (en) * 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US20040091995A1 (en) * 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
AUPR621501A0 (en) * 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
EP1578917A4 (de) 2001-07-19 2008-01-23 Perlan Therapeutics Inc Multimere proteine und verfahren zu deren herstellung und verwendung
WO2003046205A2 (en) * 2001-11-28 2003-06-05 The Burnham Institute Methods for identifying modulators of apoptosis
KR20120002613A (ko) 2002-08-12 2012-01-06 제네렉스, 인코포레이티드 폭스바이러스 및 암과 관련된 방법 및 조성물
EP1553966B1 (de) 2002-10-03 2012-08-01 Wyeth Holdings Corporation Fusionsproteine bestehend aus den humanen papillomavirus E7 und E6 Proteinen sowie immunogene Zusammensetzungen davon
AU2003284239B2 (en) * 2002-10-21 2008-08-21 Eisai Inc. Compositions and methods for treating human papillomavirus-mediated disease
WO2004073641A2 (en) 2003-02-18 2004-09-02 Kevin Slawin Induced activation in dendritic cells
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
JP2007529201A (ja) * 2004-03-11 2007-10-25 シャーンタ ウェスト インコーポレーティッド Ｒｍ１抗原の治療目的使用方法
EP1819732A2 (de) 2004-12-06 2007-08-22 Kirin Beer Kabushiki Kaisha Humane monoklonale influenza-m2-protein-antikörper und verfahren zu deren herstellung und verwendung
JP5225069B2 (ja) 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
CN1308036C (zh) * 2005-03-28 2007-04-04 浙江大学医学院附属妇产科医院 一种hpv多肽疫苗及其制备方法
KR101772375B1 (ko) * 2005-09-07 2017-08-29 신라젠(주) Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
CA2524619A1 (en) * 2005-11-22 2007-05-22 Ottawa Health Research Institute Novel stem cells, nucleotide sequences and proteins therefrom
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
US20070248539A1 (en) * 2006-04-24 2007-10-25 Shantha West Inc. AgRM2 antigen
MX2008016036A (es) * 2006-06-20 2009-04-07 Transgene Sa Vacuna viral recombinante.
EP2097517B1 (de) 2006-10-16 2014-06-04 Genelux Corporation Rekombinantes Lister-Stamm Vaccinia Virus kodierend für einen einzelkettigen anti-VEGF Antikörper
CA3058450A1 (en) 2006-10-19 2008-04-24 Baylor College Of Medicine Generating an immune response by inducing cd40 and pattern recognition receptors
EP2101813B1 (de) 2006-11-27 2014-04-02 Patrys Limited Neues glykosyliertes zielpeptid in neoplastischen zellen
CL2008000249A1 (es) * 2007-01-30 2008-05-30 Transgene Sa Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
RU2462513C2 (ru) * 2007-05-15 2012-09-27 Трансген С.А. Векторы для множественной генной экспрессии
US20090081639A1 (en) * 2007-05-31 2009-03-26 Phil Hill Assay for sensitivity to chemotherapeutic agents
GB0710538D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Vaccine
CA2690627C (en) * 2007-06-15 2014-12-02 Genelux Corporation Microorganisms for imaging and/or treatment of tumors
JP2010533718A (ja) * 2007-07-18 2010-10-28 ジェネラックス・コーポレイション 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
EP2185694A2 (de) 2007-08-02 2010-05-19 California Stem Cell, Inc. Neuronale vorläuferzellen und verfahren zur ableitung und reinigung neuronaler vorläuferzellen aus embryonischen stammzellen
JP2011500036A (ja) * 2007-10-15 2011-01-06 ザ ユニバーシティー オブ クイーンズランド 構築物系およびその使用
RU2503717C2 (ru) * 2007-11-19 2014-01-10 Трансжене Са Поксвирусные онколитические векторы
US8426163B2 (en) 2007-12-07 2013-04-23 National Health Research Institutes Production of lipidated proteins in E. coli
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
CA2738031C (en) * 2008-09-22 2022-11-29 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
US8211487B2 (en) * 2008-11-26 2012-07-03 Srinivasan Damodaran Inhibition of ice crystal growth
JP5748653B2 (ja) 2009-04-10 2015-07-15 協和発酵キリン株式会社 抗ｔｉｍ−３抗体を用いた血液腫瘍治療法
JP5694923B2 (ja) 2009-04-27 2015-04-01 協和発酵キリン株式会社 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
EP2445927B1 (de) 2009-06-22 2014-04-23 National Health Research Institutes Lipidierte tumorassoziierte antigene und immuntherapiezusammensetzungen
ES2848650T3 (es) 2009-09-14 2021-08-11 Sillajen Biotherapeutics Inc Terapia combinada contra el cáncer con virus vaccinia oncolítico
WO2011060233A1 (en) 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
JP6153866B2 (ja) 2010-05-25 2017-06-28 キアゲン ガイサーズバーグ アイエヌシー． 迅速なハイブリッド捕捉アッセイ、及び関連する戦略的に切断されたプローブ
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
AU2012204467B2 (en) 2011-01-04 2016-08-18 Sillajen, Inc. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
ES2733211T3 (es) 2011-04-15 2019-11-28 Genelux Corp Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
CN105601748B (zh) 2011-07-01 2021-08-27 恩格姆生物制药公司 用于代谢病症和疾病治疗的组合物、应用和方法
BR112014015016B1 (pt) * 2011-12-21 2023-10-03 Nykode Therapeutics ASA Proteína homodimérica de duas cadeias de aminoácidos idênticas,cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica,célula hospedeira, método de preparação de uma proteína homodimérica, método de preparação de uma vacina e vacina
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
US9783610B2 (en) 2012-04-27 2017-10-10 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
CN102787134B (zh) * 2012-07-20 2014-11-05 西安交通大学 一种用于同源重组的自转运载体及其构建的经粘膜免疫疫苗
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
EP3587455A1 (de) 2012-10-23 2020-01-01 Emory University Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
IL238323B2 (en) 2012-10-30 2023-11-01 Esperance Pharmaceuticals Inc Antibody/drug conjugates and methods of use
HK1214832A1 (zh) 2012-11-28 2016-08-05 恩格姆生物制药公司 用於代謝病症和疾病治療的組合物和方法
ES2915851T3 (es) 2012-12-27 2022-06-27 Ngm Biopharmaceuticals Inc Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares
US9790269B2 (en) 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
CA2905352A1 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
ES2791598T3 (es) 2013-06-05 2020-11-05 Bellicum Pharmaceuticals Inc Métodos para inducir apoptosis parcial utilizando polipéptidos de caspasa
EP3013945B1 (de) 2013-06-25 2020-05-27 Temple University Of The Commonwealth System Of Higher Education Aus kortikalem knochen gewonnene stammzellen
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
CN103772508B (zh) * 2014-01-15 2017-05-10 深圳泰来生物医药有限公司 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗
US10934346B2 (en) 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
AU2015312117A1 (en) 2014-09-02 2017-03-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
RU2729161C2 (ru) 2014-10-23 2020-08-04 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
JP6718444B2 (ja) 2014-11-03 2020-07-08 アカデミッシュ ザイケンホイス レイデン （エイチ．オー．ディー．エヌ． エルユーエムシー） Ｂｏｂ１に対して指向されるＴ細胞レセプターおよびその使用
WO2016118780A1 (en) 2015-01-21 2016-07-28 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
US9901639B2 (en) 2015-02-13 2018-02-27 Temple University—Of the Commonwealth System of Higher Education Bone marrow origin progenitor cell or endothelial progenitor cell in combination with DNMT1 gene therapy for vascular repair in metabolic disease
CA2978171A1 (en) 2015-03-10 2016-09-15 J.H. Frederik Falkenburg T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
WO2017096432A1 (en) 2015-12-09 2017-06-15 Admedus Vaccines Pty Ltd Immunomodulating composition for treatment
IL260030B2 (en) 2016-01-08 2025-12-01 Nykode Therapeutics ASA Therapeutic anticancer neoepitope vaccine
BR112018070948A2 (pt) 2016-04-13 2019-01-29 Orimabs Ltd. anticorpos anti-psma e utilização dos mesmos
US10512683B2 (en) * 2017-03-03 2019-12-24 Papivax Biotech Inc. Combination therapies for human papillomavirus-associated diseases comprising administration of therapeutic vaccine and recombinant virus vector
EP3621988A1 (de) 2017-05-09 2020-03-18 Bellicum Pharmaceuticals, Inc. Verfahren zur verstärkung oder änderung der signaltransduktion
WO2019036753A1 (en) 2017-08-22 2019-02-28 Monash University SCREENING TESTS, MODULATORS AND MODULATION OF RECEIVER ACTIVATION FOR ADVANCED GLYCATION TERMINAL PRODUCTS (RAGE)
US12428641B2 (en) 2017-09-15 2025-09-30 Commonwealth Scientific And Industrial Research Organisation RNA molecules
WO2019113509A2 (en) 2017-12-08 2019-06-13 Bellicum Pharmaceuticals, Inc. Methods for enhancing and maintaining car-t cell efficacy
WO2020056170A1 (en) 2018-09-12 2020-03-19 Fred Hutchinson Cancer Research Center Reducing cd33 expression to selectively protect therapeutic cells
JP2024502832A (ja) 2020-12-31 2024-01-23 アラマー バイオサイエンシーズ， インコーポレイテッド 高親和性及び／または特異性を有する結合剤分子ならびにその製造及び使用方法
IL318055A (en) 2022-07-08 2025-02-01 Viromissile Inc ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF
CN119464385B (zh) * 2024-12-04 2026-04-07 华中科技大学同济医学院附属同济医院 Matv11重组腺病毒载体、应用、制备方法及hpv治疗性疫苗

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
FR2643817B1 (fr) * 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
DE69031735T2 (de) * 1989-04-18 1998-03-12 Applied Biotechnology Inc Erzeugung von hybrid-genen und proteinen durch rekombination mittels viren

Also Published As

Publication number Publication date
ES2168258T3 (es) 2002-06-16
DK0576471T3 (da) 2002-03-11
US5719054A (en) 1998-02-17
NO933260L (no) 1993-10-22
NO310033B1 (no) 2001-05-07
CN1090239C (zh) 2002-09-04
MX9205131A (es) 1994-06-30
OA10085A (en) 1996-12-18
KR100240183B1 (ko) 2000-01-15
DE69232201T2 (de) 2002-07-11
HK1001657A1 (en) 1998-07-03
BR9205771A (pt) 1994-06-07
EP0576471B1 (de) 2001-11-14
GB9105383D0 (en) 1991-05-01
JPH06505626A (ja) 1994-06-30
CN1064892A (zh) 1992-09-30
CA2106069A1 (en) 1992-09-15
EP0576471A1 (de) 1994-01-05
AU1414792A (en) 1992-10-21
WO1992016636A1 (en) 1992-10-01
AU665531B2 (en) 1996-01-11
NO933260D0 (no) 1993-09-13
DE69232201D1 (de) 2001-12-20

Similar Documents

Publication Publication Date Title
ATE208824T1 (de) Für proteine des menschlichen papillomavirus kodierende rekombinante virusvektoren
EP0575491A4 (de) Gentechnologisch hergestellter stamm für impfstoffe.
HUP9802217A2 (hu) Rekombináns MVA-vírus és alkalmazása
GB9717953D0 (en) Vaccine
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
EP0766569A4 (de) Aaw-hülltransporter für den molekularen transfer
DE69430071D1 (de) Herstellung von rekombinanten proteinen in einem rinderadenovirus-expressionsvektorsystem
NO964862L (no) Papillomavirusvaksiner
HUP0001930A2 (hu) Módosított TNFalfa-molekulák, ilyen módosított TNFalfa-molekulákat kódoló DNS, valamint ilyen módosított TNFalfa-molekulát és DNS-t tartalmazó vakcinák
ATE132534T1 (de) Rekombinanter impfstoff
ES8505719A1 (es) Procedimiento de preparar mutantes de delecion vivos y metodo de preparar vacunas
Diniz et al. Enhanced therapeutic effects conferred by an experimental DNA vaccine targeting human papillomavirus-induced tumors
WO2000061737A3 (en) Production of attenuated negative stranded RNA virus vaccines
IL77694A (en) Canine parvovirus vaccines comprising viruses of the canine parvovirus strain 154 or viruses derived therefrom by additional cell culture passaging
ATE246247T1 (de) Varianten des humanen rekombinanten interferon- gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität
DE69333751D1 (de) Nicht-verbreitendes lebendes herpesvirusvakzin
ATE223492T1 (de) Mutanten des infektiösen rinder rhinotracheitis- virus und impfstoffe
CN109568574B (zh) sPD1蛋白和/或sPD1基因作为免疫佐剂的应用
RU2000122617A (ru) Самореплицирующийся рекомбинантный вектор, способ его получения, вакцина для иммунизации против вич с помощью днк, содержащая указанный вектор, способ лечения или профилактики вич и клетка-хозяин, содержащая указанный вектор
IL168374A (en) Vaccines against west nile virus
CA2105277A1 (en) Genetically engineered vaccine strain
RU93056615A (ru) Вектор, способ получения вектора, способ получения лекарственного препарата, способ активизации иммунитета
ES2074965A1 (es) Virus mutante recombinante de rinotraqueitis infecciosa bovina y vacunas que lo contienen.
ZA916106B (en) Cloning and expression of a rhoptry-associated protein of p.falciparum
Allaudin Development of Gene Deleted Recombinant Pseudorabies Virus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee